Patients with metabolic syndrome have significantly worse hospitalization and mortality rates due to COVID-19. Hypertension, diabetes, and obesity are common comorbidities associated with metabolic syndrome, as described in a new study published in the peer-reviewed journal Metabolic Syndrome and Related Disorders. Click here to read the article now.
"Our results demonstrate that patients with metabolic syndrome were 77% more likely to be hospitalized, 56% more likely to be admitted to the intensive care unit, and 81% more likely to die from COVID-19, according to Sangeeta Kashyap, MD, from the Cleveland Clinic, and coauthors. "Obesity, hyperglycemia, dyslipidemia, and hypertension are modifiable components of metabolic syndrome that would reduce morbidity and mortality of COVID-19," conclude the investigators.
"This paper is a timely reminder of the need to appreciate individual risk factors when assessing outcomes of COVID-19 - and that obesity is probably the most important (and modifiable) risk factor that explains the increase in risk. For example, the presence of metabolic syndrome doubled the death rate from 3% to 6%. Half of all patients with metabolic syndrome were hospitalized - in contrast to 25% of those without metabolic syndrome," says Dr. Adrian Vella, Editor-in-Chief of Metabolic Syndrome and Related Disorders and Professor, Mayo Clinic College of Medicine, Rochester, MN
About the Journal
Metabolic Syndrome and Related Disorders is the only peer-reviewed journal to focus solely on the pathophysiology, recognition, and treatment of metabolic syndrome. Led by Adrian Vella, MD, FRCP (Edin.), Professor of Medicine, Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, MN, the Journal covers a range of topics including insulin resistance, central obesity, glucose intolerance, dyslipidemia with elevated triglycerides, predominance of small dense LDL-cholesterol particles, hypertension, endothelial dysfunction, and oxidative stress and inflammation. Complete tables of content and a sample issue may be viewed on the Metabolic Syndrome and Related Disorders website.
About the Publisher
Mary Ann Liebert, Inc., is known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 100 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website.
